EC approves change in posology of Circadin from 3 weeks to 3 months of treatment
Neurim Pharmaceuticals confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment...
View ArticleGE Healthcare seeks approval to supply Optison to EU market from Oslo...
GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison 0.19 mg/ml dispersion for injection...
View ArticleLixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE...
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
View ArticleUnituxin (dinutuximab) granted EC Marketing Authorisation for treatment of...
United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients...
View ArticleEC approves change in posology of Circadin from 3 weeks to 3 months of treatment
Neurim Pharmaceuticals confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment...
View ArticleGE Healthcare seeks approval to supply Optison to EU market from Oslo...
GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison 0.19 mg/ml dispersion for injection...
View ArticleLixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE...
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
View ArticleUnituxin (dinutuximab) granted EC Marketing Authorisation for treatment of...
United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients...
View Article